用奥氮平和阿立哌唑成功治疗了一名从利培酮转为帕利哌酮后出现前列腺增生的精神分裂症患者。

IF 2 Q3 NEUROSCIENCES
Neuropsychopharmacology Reports Pub Date : 2024-12-01 Epub Date: 2024-11-03 DOI:10.1002/npr2.12501
Saki Kawahara, Kazuyuki Watanabe, Kazuhiko Inazumi, Makoto Kimura, Yuki Hirose, Hiraki Koishikawa
{"title":"用奥氮平和阿立哌唑成功治疗了一名从利培酮转为帕利哌酮后出现前列腺增生的精神分裂症患者。","authors":"Saki Kawahara, Kazuyuki Watanabe, Kazuhiko Inazumi, Makoto Kimura, Yuki Hirose, Hiraki Koishikawa","doi":"10.1002/npr2.12501","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Ischemic priapism is a rare pathological condition, and delayed intervention can result in irreversible sequelae. Most cases are attributed to the use of antipsychotics. The blockade of α1-adrenergic receptors is thought to be associated with the disease onset, although data supporting this hypothesis are lacking. No consensus regarding the optimal choice of medication is available.</p><p><strong>Case presentation: </strong>A 59-year-old man with schizophrenia, who had been receiving long-acting injections of risperidone, developed ischemic priapism after receiving paliperidone treatment. Following improvement in ischemic priapism, we administered a combination of aripiprazole and olanzapine, which improved his psychiatric symptoms. We did not observe any recurrence of ischemic priapism.</p><p><strong>Conclusions: </strong>Switching the antipsychotic drug causing ischemic priapism to patients having a relatively low affinity for α1-adrenergic receptors may enable the treatment of schizophrenia without recurrence of ischemic priapism. In addition to the affinity for α1-adrenergic receptor, differences in metabolic enzyme types and antipsychotic doses may be involved in the occurrence of ischemic priapism. Accumulating evidence is necessary to establish guidelines for selecting medication of patients with ischemic priapism.</p>","PeriodicalId":19137,"journal":{"name":"Neuropsychopharmacology Reports","volume":" ","pages":"863-866"},"PeriodicalIF":2.0000,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11609731/pdf/","citationCount":"0","resultStr":"{\"title\":\"Successful treatment with olanzapine and aripiprazole of a schizophrenic patient who developed priapism after switching from risperidone to paliperidone.\",\"authors\":\"Saki Kawahara, Kazuyuki Watanabe, Kazuhiko Inazumi, Makoto Kimura, Yuki Hirose, Hiraki Koishikawa\",\"doi\":\"10.1002/npr2.12501\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background: </strong>Ischemic priapism is a rare pathological condition, and delayed intervention can result in irreversible sequelae. Most cases are attributed to the use of antipsychotics. The blockade of α1-adrenergic receptors is thought to be associated with the disease onset, although data supporting this hypothesis are lacking. No consensus regarding the optimal choice of medication is available.</p><p><strong>Case presentation: </strong>A 59-year-old man with schizophrenia, who had been receiving long-acting injections of risperidone, developed ischemic priapism after receiving paliperidone treatment. Following improvement in ischemic priapism, we administered a combination of aripiprazole and olanzapine, which improved his psychiatric symptoms. We did not observe any recurrence of ischemic priapism.</p><p><strong>Conclusions: </strong>Switching the antipsychotic drug causing ischemic priapism to patients having a relatively low affinity for α1-adrenergic receptors may enable the treatment of schizophrenia without recurrence of ischemic priapism. In addition to the affinity for α1-adrenergic receptor, differences in metabolic enzyme types and antipsychotic doses may be involved in the occurrence of ischemic priapism. Accumulating evidence is necessary to establish guidelines for selecting medication of patients with ischemic priapism.</p>\",\"PeriodicalId\":19137,\"journal\":{\"name\":\"Neuropsychopharmacology Reports\",\"volume\":\" \",\"pages\":\"863-866\"},\"PeriodicalIF\":2.0000,\"publicationDate\":\"2024-12-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11609731/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Neuropsychopharmacology Reports\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1002/npr2.12501\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2024/11/3 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"Q3\",\"JCRName\":\"NEUROSCIENCES\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Neuropsychopharmacology Reports","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1002/npr2.12501","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/11/3 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"NEUROSCIENCES","Score":null,"Total":0}
引用次数: 0

摘要

背景:缺血性前列腺增生症是一种罕见的病理状态,延误干预会导致不可逆转的后遗症。大多数病例归因于抗精神病药物的使用。阻断α1-肾上腺素能受体被认为与发病有关,但缺乏支持这一假设的数据。目前还没有关于最佳药物选择的共识:一名59岁的精神分裂症患者一直在接受长效利培酮注射,在接受帕利哌酮治疗后出现了缺血性尿崩症。缺血性尿崩症好转后,我们给他服用了阿立哌唑和奥氮平的联合药物,从而改善了他的精神症状。我们没有发现缺血性尿崩症复发:结论:将导致缺血性尿崩症的抗精神病药物换成对α1-肾上腺素能受体亲和力相对较低的药物,可以在治疗精神分裂症的同时避免缺血性尿崩症复发。除了对α1-肾上腺素能受体的亲和力外,代谢酶类型和抗精神病药物剂量的差异也可能与缺血性猝死的发生有关。有必要积累证据,以制定缺血性尿崩症患者的用药指南。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Successful treatment with olanzapine and aripiprazole of a schizophrenic patient who developed priapism after switching from risperidone to paliperidone.

Background: Ischemic priapism is a rare pathological condition, and delayed intervention can result in irreversible sequelae. Most cases are attributed to the use of antipsychotics. The blockade of α1-adrenergic receptors is thought to be associated with the disease onset, although data supporting this hypothesis are lacking. No consensus regarding the optimal choice of medication is available.

Case presentation: A 59-year-old man with schizophrenia, who had been receiving long-acting injections of risperidone, developed ischemic priapism after receiving paliperidone treatment. Following improvement in ischemic priapism, we administered a combination of aripiprazole and olanzapine, which improved his psychiatric symptoms. We did not observe any recurrence of ischemic priapism.

Conclusions: Switching the antipsychotic drug causing ischemic priapism to patients having a relatively low affinity for α1-adrenergic receptors may enable the treatment of schizophrenia without recurrence of ischemic priapism. In addition to the affinity for α1-adrenergic receptor, differences in metabolic enzyme types and antipsychotic doses may be involved in the occurrence of ischemic priapism. Accumulating evidence is necessary to establish guidelines for selecting medication of patients with ischemic priapism.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Neuropsychopharmacology Reports
Neuropsychopharmacology Reports Psychology-Clinical Psychology
CiteScore
3.60
自引率
4.00%
发文量
75
审稿时长
14 weeks
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信